Geron CEO: Getting Imetelstat Data Wanted By FDA Will Be “Difficult”
This article was originally published in The Pink Sheet Daily
Executive Summary
Concerned about chronic liver injury, FDA halts development of Geron’s telomerase inhibitor imetelstat, the only drug left standing in Geron’s pipeline, and requests data for patients who discontinued treatment in Geron-sponsored plus non-Geron studies.